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Abstract Dehydrogenase/reductase (SDR family) member 9
(DHRS9) is aberrantly expressed in colorectal cancer (CRC),
but its prognostic value is unknown. The aim of the work was
to investigate the prognostic significance of DHRS9 expression
in CRC. We found that DHRS9 was frequently downregulated
in CRC clinical samples at both the messenger RNA (mRNA)
and protein levels. Decreased expression of DHRS9 was sig-
nificantly correlated with increased lymph node metastasis (p=
0.032), advanced tumor–node–metastasis (TNM) stage (p=
0.021), increased disease recurrence (p=0.001), and death
(p=0.014). Kaplan–Meier analysis indicated that low DHRS9
expression predicted poor disease-free survival (p=0.003) and
disease-specific survival (p=0.021). Cox multivariate analysis
revealed that reduced expression of DHRS9 was an
independent unfavorable prognostic indicator for CRC. Fur-
thermore, combination of DHRS9 with TNM stage was a more
powerful predictor of poor prognosis than either of the two
parameters alone. Our results suggest that decreased expression
of DHRS9 correlates with tumor progression and may serve as
a potential prognostic biomarker in CRC.
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Introduction
Colorectal cancer (CRC) is one of the most commonly diag-
nosed cancers worldwide, with an estimated 1.4 million cases
and 693,900 deaths occurring in 2012 [1]. Although the inci-
dence of CRC in high-risk/high-income countries has varied
over the past 20 years, it is increasing in certain historically
low-risk countries, such as Spain and several countries in
Eastern Europe and East Asia, which have been ascribed to
changes in dietary patterns and risk factors toward a so-called
Western lifestyle including unhealthy diet, obesity, and
smoking [2–5]. In addition, increases in CRC mortality rates
have been observed in countries that have more limited re-
sources and increasing incidence [6–8]. At present, classifica-
tion according to tumor–node–metastasis (TNM) stage pro-
vides valuable prognostic information and guides therapy de-
cisions for CRC patients; nevertheless, clinical outcome dif-
fers greatly even among patients of the same TNM category
[2]. Thus, there is an urgent need to search for valuable bio-
markers to improve prognosis prediction and clinical outcome
of patients with CRC.
Dehydrogenase/reductase (SDR family) member 9
(DHRS9), also known as retinol dehydrogenase L (RDHL),
has been identified as a member of the short-chain
dehydrogenases/reductase (SDR) family that converts reti-
nol to retinal. Previous studies demonstrated that DHRS9 is
involved in the biosynthesis of all-trans-retinoic acid
(atRA), which displays important anti-tumor activity
through inhibition of cell proliferation, induction of cell
differentiation, and apoptosis and has been used in several
cancer therapies including acute promyelocytic leukemia,
squamous cell carcinoma, neuroblastoma, and hepatocellu-
lar carcinoma [9–13]. The enzymatic activity of DHRS9
was firstly characterized by Soref et al. in airway epitherial
cells (referred to as hRDH-TBE in their publication) [14].
Later, Jette et al. reported that DHRS9 messenger RNA
(mRNA) was primarily expressed in the colon, and its ex-
pression was low but detectable in the heart, spleen, pla-
centa, and lung [15]. Using microarray and reverse
transcriptase-PCR analysis, they demonstrated that DHRS9
was frequently and significantly downregulated in colon
adenomas and carcinomas as compared with normal colon
tissues. Consistent with the data from the adenoma and
carcinoma samples, they found that colon-cancer-derived
cell lines expressed low or undetectable levels of DHRS9
and displayed poor conversion of retinol to retinoic acid
when compared to normal epithelial cells. Recently, a sig-
nificant decreased expression of DHRS9 mRNA in CRC
has also been confirmed by Kropotova et al. [10]. Mecha-
nistic investigations revealed that reintroduction of the tu-
mor suppressor adenomatous polyposis coli (APC) into the
APC-deficient colon carcinoma cell line HT29 resulted in
increased mRNA expression of DHRS9 via the transcrip-
tion factor CDX2 [15]. In addition, DHRS9 could be in-
duced by the lytic Epstein–Barr virus (EBV) immediate–
early protein, BZLF1, in AGS gastric carcinoma cells con-
taining the lytic form of EBV infection and EBV-positive
Burkitt lymphoma cells [9]. Since lack of retinoic acid
biosynthesis has been proposed as a mechanism contribut-
ing to the development of colon adenomas and carcinomas,
we hypothesized that dysregulation of DHRS9 expression
may be associated with aggressive clinical behavior of
CRC. However, the clinical relevance of DHRS9 expres-
sion in CRC has not been investigated.
In the present study, we detected both the mRNA and the
protein expression levels of DHRS9 in CRC clinical samples
and further analyzed the correlation of DHRS9 expression
with clinical features and with patient survival. Our results
demonstrated that decreased expression of DHRS9 correlates
with tumor progression and might serve as an independent
unfavorable prognostic indicator for patients with CRC.
Materials and methods
Patients and follow-up
Formalin-fixed paraffin-embedded tissue specimens from
163 stages I–III CRC patients who received curative sur-
gery in 150th Hospital of PLA (Luoyang, China) from
April 2007 to September 2008 were retrieved for immuno-
histochemistry. The study cohort consisted of patients with
CRC as confirmed by pathological analysis. Distribution
of the continuous variables of the study cohort is listed in
Table 1. Detailed clinicopathologic characteristics of the
patients are listed in Table 2. The follow-up period was
defined as the interval from the date of surgery to the date
of death or last follow-up. The latest follow-up was up-
dated in September 2014. Disease-specific survival (DSS)
was defined as the interval from the date of surgery to the
date that the patient died of CRC. Patients alive at the end
of follow-up were censored. Disease-free survival (DFS)
was defined as the interval from the date of surgery to the
date of disease recurrence; if recurrence was not diag-
nosed, patients were censored on the date of death or last
follow-up. Patients were excluded from the study cohorts
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with the following exclusion criteria: previously received
any anti-cancer therapy; impaired heart, lung, liver, or kid-
ney function; and previous malignant disease. TNM stag-
ing was classified according to the American Joint Com-
mittee on Cancer staging manual (seventh edition).
Fresh-frozen CRC samples obtained from 58 stages I–III
primary CRC patients who received curative surgery in 150th
Hospital of PLA from April 2013 to September 2013 were
used for quantitative polymerase chain reaction (qPCR) and
Western blot analysis. Written informed consent was obtained
from each patient, and this study was approved by the Ethical
Committee of 150th Hospital of PLA.
Table 1 Distribution of continuous variables of the study cohort (n=
163)
Variable Median Mean±SEM Range Percentile
25th 75th
Age (years) 66.0 65.5±0.9 31.0–91.0 58.0 74.0
Tumor size (cm) 5.0 5.1±0.2 1.1–15.0 4.0 6.5
DSS (months) 75.0 57.9±2.3 1.0–89.0 34.0 80.0
DFS (months) 62.0 50.7±2.4 1.0–89.0 19.0 78.0
SEM standard error of the mean, DSS disease-specific survival, DFS
disease-free survival
Table 2 Association between
DHRS9 expression and
clinicopathologic characteristics
of CRC patients in the study
cohort
Characteristics No. of patients (%) DHRS9 expression
Low (%) High (%) p valuea
(n=163) (n=83) (n=80)
Age (years) 0.573
<60 44 (27.0) 24 (28.9) 20 (25.0)
≥60 119 (73.0) 59 (71.1) 60 (75.0)
Sex 0.716
Female 71 (43.6) 35 (42.2) 36 (45.0)
Male 92 (56.4) 48 (57.8) 44 (55.0)
Tumor location 0.605
Rectum 68 (41.7) 33 (39.8) 35 (43.8)
Colon 95 (58.3) 50 (60.2) 45 (56.2)
Differentiation grade 0.780
Well 12 (7.3) 5 (6.0) 7 (8.8)
Moderate 115 (70.6) 60 (72.3) 55 (68.8)
Poor 36 (22.1) 18 (21.7) 18 (22.4)
Tumor size (cm) 0.103
<5 67 (41.1) 29 (34.9) 38 (47.5)
≥5 96 (58.9) 54 (65.1) 42 (52.5)
Local invasion 0.860
T1–T2 17 (10.4) 9 (10.8) 8 (10.0)
T3–T4 146 (89.6) 74 (89.2) 72 (90.0)
Lymph node metastasis 0.032
N0 89 (54.6) 38 (45.8) 51 (63.8)
N1 47 (28.8) 26 (31.3) 21 (26.2)
N2 27 (16.6) 19 (22.9) 8 (10.0)
TNM stage 0.021
I+II 89 (54.6) 38 (45.8) 51 (63.8)
III 74 (45.4) 45 (54.2) 29 (36.2)
Recurrence 0.001
No 76 (46.6) 28 (33.7) 48 (60.0)
Yes 87 (53.4) 55 (66.3) 32 (40.0)
Death 0.014
No 90 (55.2) 38 (45.8) 52 (65.0)
Yes 73 (44.8) 45 (54.2) 28 (35.0)
a Pearson chi-square test or Fisher exact test was used for comparison between subgroups. Bold type indicates
statistical significance
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Real-time qPCR analysis
Real-time qPCR was performed as described previously [16].
Briefly, total RNAs were isolated from frozen specimens
using TRIzol Reagent (Invitrogen). Reverse transcription
(RT) was performed using RevertAidTM First Strand cDNA
Synthesis Kit (Fermentas) according to the manufacturer’s
instructions. After the RT reaction, the cDNA template was
quantitated using real-time PCR technology (qPCR). qPCR
was performed on ABI Prism 7500 Sequence Detection Sys-
tem with SYBR Premix Ex TaqTM II (Takara) using the
2−ΔΔCT method. Gene expression results were normalized
by internal control β-actin. The primers used in this study
are as follows: DHRS9 (NM_001142270.1) forward 5′-
TTCCTTTGGCTGCTGACAGG-3 ′ and reverse 5 ′-
ATTAGGAGGCCTAGCACCCA-3′, and β-actin forward
5′-AATCGTGCGTGACATTAAGGAG-3′ and reverse 5′-
ACTGTGTTGG CGTACAGGTCTT-3′. Each sample was
tested in duplicate.
Western blot analysis
Western blotting was performed as described previously [17].
Briefly, tumor specimens were prepared in lysis buffer [Tris–
HCl (20 mM), pH 7.4, NaCl (150 mM), glycerol (10 %),
Nonidet P-40 (0.2 %), EDTA (1 mM), EGTA (1 mM), PMSF
(1 mM), NaF (10 mM), aprotinin (5 mg/ml), leupeptin
(20 mM), and sodium orthovanadate (1 mM)] and centrifuged
at 12,000g for 30 min. Protein concentrations were measured
using the BCA assay. Immunoblotting was performed using a
primary antibody specific for DHRS9 (Abnova, H00010170-
B01P), and immunocomplexes were incubated with goat anti-
mouse fluorescein-conjugated secondary antibodies and then
detected using an Odyssey fluorescence scanner (Li-Cor,
Gene Company). β-actin was used as a loading control (Santa
Cruz Biotechnology, sc-47778).
Immunohistochemistry
Immunohistochemistry of paraffin-embedded tissue sections
was performed as described previously [18]. Briefly, sections
were deparaffinized and rehydrated. The endogenous peroxi-
dase activity was blocked with 3%H2O2 for 10min. Antigens
were retrieved with citrate buffer (10 mM, pH 6.0) for 15 min
at 100 °C in a microwave oven. After blocking, the sections
were incubated with a primary anti-DHRS9 Antibody
(LifeSpan Biosciences, LS-C145077) with 1:200 dilution at
4 °C overnight in a moist chamber followed by incubation
with an anti-rabbit peroxidase-conjugated secondary antibody
(Santa Cruz) at room temperature for 30 min. Finally, the
visualization signal was developed with diaminobenzidine
(Dako), and the slides were counterstained with hematoxylin.
Stained sections were evaluated in a blinded manner with-
out prior knowledge of the clinical data using the German
immunoreactive score (IRS) as described previously [16,
19]. Briefly, staining intensity was graded as B0^ (negative),
B1^ (weak), B2^ (moderate), and B3^ (strong); staining extent
was graded as B0^ (<5 %), B1^ (5–25 %), B2^ (25–50 %), B3^
(50–75 %), or B4^ (>75 %). Values of the staining intensity
and the staining extent were multiplied as a final IRS of
DHRS9 expression. The median IRS value of intratumoral
DHRS9 expression was chosen as the cutoff for high and
low DHRS9 expression levels based on a measure of hetero-
geneity according to the log-rank test with respect to DSS, as
described previously [20, 21]. An IRS of ≥3 was used to
define tumors with high DHRS9 expression, and an IRS of
<3 was used to indicate tumors with low DHRS9 expression.
Discrepancies in the IRS were resolved by discussing together
with other pathologists to reach a consensus.
Statistical analysis
Mann–Whitney U test was used to compare DHRS9 levels
between groups. Pearson chi-square test or Fisher exact test
was used to analyze the relationship between DHRS9 expres-
sion and clinical features. Kaplan–Meier analysis with log-
rank test was used to compare patients’ survival between sub-
groups. The effect of each variable on survival was deter-
mined by the Cox multivariate regression analysis. All statis-
tical analyses were carried out using SPSS PASW Statistics
18.0 software (SPSS, Inc., Chicago, IL), and p values <0.05
were considered to be statistically significant.
Results
Expression of DHRS9 in primary CRC tissues
The expression levels of DHRS9 mRNA in 58 paired human
CRC tissues and corresponding adjacent normal mucosa tis-
sues were quantified by real-time qPCR method. As shown in
Fig. 1a, DHRS9 transcripts were significantly decreased in the
cancerous tissues relative to the matched normal mucosa tis-
sues (p<0.001). In addition, Western blot assay was per-
formed to determine the protein expression levels of DHRS9
on the same corresponding samples. Consistently, DHRS9
protein expression was also significantly lower in cancerous
tissues than in adjacent normal counterparts (Fig. 1b).
We next detected the phenotypic expression patterns of
DHRS9 protein in 163 paired paraffin-embedded CRC and
corresponding adjacent normal mucosa specimens using im-
munohistochemistry. Representative staining of DHRS9 in
CRC tissues is shown in Fig. 1c, and positive expression of
DHRS9 was observed in the cytoplasm. DHRS9 protein ex-
pression was detected in 57.7 % (94/163) of the cancerous
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samples. Among them, 38.7% (63/163), 18.4% (30/163), and
0.6 % (1/163) of the cases show weak, moderate, and strong
staining of DHRS9 protein, respectively. In contrast, 45.4 %
(74/163), 36.8 % (60/163), and 9.2 % (15/163) of the adjacent
normal mucosa specimens show weak, moderate, and strong
staining of DHRS9, respectively (Fig. 1d). Thus, DHRS9 was
Fig. 1 DHRS9 is frequently downregulated in CRC. a The
expression levels of DHRS9 mRNA in 58 paired human primary
CRC and corresponding adjacent normal mucosa specimens were
determined by real-time qPCR methods. Gene expression results
were normalized by internal control β-actin (T, tumor tissues; N,
adjacent normal tissues). b Protein levels of DHRS9 in the same 58
paired CRC and corresponding adjacent normal specimens were
determined by Western blot assay. β-actin was used as a loading
control. The relative protein expression of DHRS9 was quantified and
normalized to β-actin. Each N was arbitrarily designated 1.0. (T, tumor;
N, adjacent normal tissues) c Representative immunohistochemical
expression patterns of DHRS9 in cancerous and adjacent normal
mucosa specimens are shown (magnification: left panel, ×100; right
panel, ×400). d Percentage of cases with different staining intensity of
DHRS9 in the tumor or adjacent normal tissues in the study cohort
(p<0.001)
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frequently downregulated in CRC tissues at both the mRNA
and protein levels.
Correlation of DHRS9 expression with clinicopathologic
features
The association between DHRS9 expression levels and clini-
copathologic characteristics of CRC patients is summarized in
Table 2. Reduced expression of DHRS9 was significantly cor-
related with increased lymph node metastasis (p=0.032), ad-
vanced TNM stage (p=0.021), increased disease recurrence
(p=0.001), and death (p=0.014). However, there were no sig-
nificant associations between DHRS9 expression and patient
age (p=0.573), sex (p=0.716), tumor location (p=0.605), tu-
mor differentiation grade (p=0.780), tumor size (p=0.103), or
local invasion (p=0.860).
Association of DHRS9 expression with prognosis of CRC
patients
The 163 CRC patients were classified into high and low
DHRS9 expression subgroups using its median IRS value as
the cutoff point. The Kaplan–Meier analysis showed that pa-
tients in the low DHRS9 group had a significantly shorter
disease-free survival (DFS) and worse disease-specific surviv-
al (DSS) than those in the high DHRS9 group (p=0.003 and
p=0.021, respectively; Fig. 2a, b). The cumulative 5-year
DFS and DSS rate was 61.3 and 66.3 % in patients with
high-DHRS9 tumors, whereas it was only 39.8 and 53.0 %
in those with low DHRS9 tumors, respectively.
To assess whether DHRS9 expression represents an inde-
pendent prognostic indicator in CRC, the effect of each vari-
able on survival was determined by the Cox regression anal-
ysis. Univariate analyses revealed that DHRS9 expression,
TNM stage, and patient age were significantly associated with
DSS, while DHRS9 expression and TNM stage were signifi-
cantly associated with DFS (Table 3). The variables that sig-
nificantly correlated with survival in the univariate analysis
were further assessed by multivariate analysis. The results of
the multivariate analysis confirmed that DHRS9 expression
(hazard ratio (HR)=1.715, 95 % confidence interval
(95%CI)=1.058–2.778, p=0.029), TNM stage (HR=3.047,
95%CI=1.867–4.974, p<0.001), and patient age (HR=
2.953, 95%CI=1.592–5.477, p=0.001) were independent
prognostic factors for DSS. In addition, DHRS9 expression
(HR=1.767, 95%CI=1.136–2.755, p=0.012) and TNM stage
(HR=4.528, 95%CI=2.830–7.244, p<0.001) were indepen-
dent prognostic factors for DFS (Table 3).
Since either decreased DHRS9 expression or advanced
TNM stage predicts a poor prognosis of patients with CRC,
we then observed the combination of DHRS9 expression and
TNM stage as a predictor of clinical outcome. Importantly, the
combination of these two parameters provided an improved
prognostic value in comparison with the evaluation of either
the TNM stage or DHRS9 expression alone (Fig. 3a, b).
Discussion
In the present study, we reported that DHRS9 expression was
both transcriptionally and translationally downregulated in
primary CRC clinical tissues compared with corresponding
adjacent normal mucosa tissues. In addition, reduced expres-
sion of DHRS9 was significantly correlated with a variety of
important clinicopathologic parameters including lymph node
metastasis, TNM stage, disease recurrence, and vital status.
Finally, survival analysis revealed that lower DHRS9 expres-
sion in tumors significantly predicted poorer DFS and DSS
and was an independent unfavorable prognostic indicator for
CRC.Moreover, combination of DHRS9with TNM stage had
a better survival predictive power than either of the two pa-
rameters alone.
Decreased expression of DHRS9 has been documented
previously by Jette et al. and Kropotova et al. at the mRNA
level [10, 15]. Our real-time qPCR data were also consistent
with their findings. Of note, we observed a significant
Fig. 2 Kaplan–Meier survival
analysis for CRC patients
according to DHRS9 expression
status. Kaplan–Meier curves for
disease-free survival (a) or
disease-specific survival (b) of the
163 CRC patients according to
DHRS9 expression status (high or
low expression). The p value was
determined using the log-rank
test. The absolute number of
patients at risk in each subgroup is
listed below
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decrease in DHRS9 mRNA level (over twofold) in 65.5 %
(38/58) of the cancerous specimens tested, while Jette et al.
reported that expression of DHRS9 was decreased at least
twofold in 90 % (9/10) of carcinoma samples. This discrep-
ancy may be attributed to the different ethnic groups studied,
sample size, or endogenous control used for normalization. In
addition, our subsequent Western blot assay on the same cor-
responding samples confirmed that DHRS9 protein was
significantly downregulated in 74.1 % (43/58) of the cancer-
ous tissues tested. Furthermore, immunohistochemical analy-
ses of 163 paired CRC samples showed that the immunoreac-
tivity of DHRS9 protein was observed in the cytoplasm, and
91.4 % (149/163) of the normal colorectal mucosa tissues
tested were classified as DHRS9-positive, whereas only
57.7 % (94/163) of the cancerous samples were classified as
DHRS9-positive. Among them, 46 % (75/163) of the normal
Table 3 Univariate and multivariate analyses of DHRS9 expression and patients’ survival
Variables Categories Univariate analysis Multivariate analysisa
HR 95%CI p valueb HR 95%CI p valueb
Disease-specific survival
Age (years) ≥60/<60 1.996 1.095–3.636 0.024 2.953 1.592–5.477 0.001
Sex Male/female 0.695 0.439–1.100 0.120
Tumor location Colon/rectum 0.947 0.595–1.506 0.818
Tumor size (cm) ≥5/<5 1.037 0.649–1.657 0.880
Differentiation grade Poor/well+moderate 1.616 0.966–2.705 0.068
TNM stage III/I+ II 2.841 1.763–4.577 <0.001 3.047 1.867–4.974 <0.001
DHRS9 expression Low/high 1.730 1.079–2.770 0.023 1.715 1.058–2.778 0.029
Disease-free survival
Age (years) ≥60/<60 1.568 0.943–2.610 0.083
Sex Male/female 0.748 0.491–1.140 0.177
Tumor location Colon/rectum 0.935 0.611–1.430 0.756
Tumor size (cm) ≥5/<5 1.017 0.662–1.561 0.939
Differentiation grade Poor/well+moderate 1.432 0.882–2.323 0.146
TNM stage III/I + II 4.093 2.587–6.475 <0.001 4.528 2.830–7.244 <0.001
DHRS9 expression Low/high 1.927 1.245–2.985 0.003 1.767 1.136–2.755 0.012
HR hazard ratio, 95%CI 95 % confidence interval, TNM tumor–node–metastasis
aMultivariate models were adjusted for age, sex, tumor location, tumor size, differentiation grade, and TNM stage
b Bold type indicates statistical significance
Fig. 3 Kaplan–Meier survival analysis for CRC patients according to
DHRS9 expression combined with TNM stage status. Kaplan–Meier
curves for disease-free survival (a) or disease-specific survival (b) of
the 163 CRC patients according to DHRS9 expression status (high or
low expression) combined with TNM stage status (early or advanced
stage). The p value was determined using the log-rank test. The absolute
number of patients at risk in each subgroup is listed below
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mucosa tissues examined were moderate–strong staining of
DHRS9 protein, while only 19 % (31/163) of the cancerous
tissues showed virtually the same immunoreactivity. Thus, our
results definitely confirmed the significant downregulation of
DHRS9 expression in CRC at both the mRNA and the protein
level. The reported induction of DHRS9 by the tumor sup-
pressor gene APC [15] may, at least partly, explain the reason
why DHRS9 expression is reduced in CRC. Nevertheless, the
detail mechanism for DHRS9 downregulation in CRC re-
mains to be clarified.
Interestingly, according to our results, decreased expres-
sion of DHRS9 protein in CRC was significantly correlat-
ed with increased lymph node metastasis, advanced TNM
stage, increased disease recurrence, and patient death, in-
dicating that DHRS9 might be negatively involved in the
progression of CRC. It is well established that atRA exerts
multiple anti-tumor effects by inhibiting proliferation, re-
ducing colony formation, blocking anchorage-independent
growth, promoting differentiation, inducing apoptosis, and
suppressing invasiveness of cancer cell [12, 22–27], and
significantly impaired atRA biosynthesis has been noted in
a variety of human malignancies, such as prostate cancer,
breast cancer, ovarian cancer, gastric cancer, and CRC [15,
28–31]. Meanwhile, DHRS9 belongs to the atRA-
generating enzymes [13, 15, 32], and its reduced mRNA
expression has also been observed in CRC tissues and
CRC-derived cell lines [10, 15]. Moreover, Jette et al.
found that diminished atRA biosynthesis activity was ac-
companied with decreased DHRS9 expression in a number
of CRC-derived cell lines and that reintroduction of the
tumor suppressor APC into APC-deficient colon cancer
cells not only induced DHRS9 expression but also in-
creased the conversion of retinol to retinoic acid [15].
Therefore, we hypothesized that DHRS9 might, at least
partly, influence the progression of CRC through atRA-
related pathway. To test this hypothesis, we detected the
mRNA expression of DHRS9 and some downstream tar-
gets of atRA or CRC cell progression related genes. Wang
et al. previously showed that atRA induces the tumor
suppressor gene XAF1 expression through an interferon
regulatory factor-1 element in colon cancer [33], and
Woo et al. recently reported that atRA induces expression
of the tumor suppressor gene E-cadherin via inhibition of
DNA methylation in HCT116 cells [34]. Interestingly, we
found that DHRS9 mRNA expression was positively cor-
related with XAF1 and E-cadherin mRNA expression in
the 58 CRC samples tested (data not shown). These pre-
liminary findings also support a tumor inhibitory role of
DHRS9 in human CRC. Nevertheless, it should be noted
that whether reduction of DHRS9 indeed contributes to
the development and progression of CRC remains to be
carefully determined, for the decrease in DHRS9 expres-
sion may also be the result of other factors that lead to
cancer progression, rather than downregulation of DHRS9
leading to cancer progression. Further in vitro and in vivo
studies using gain-of-function as well as loss-of-function
strategies are warranted to address this issue.
Another interesting finding of the present study was the
prognostic significance of DHRS9 in CRC. Decreased
DHRS9 protein expression was significantly associated with
shortened DFS and DSS of CRC patients. In univariate anal-
ysis, DHRS9 protein emerged as a significant prognostic fac-
tor of clinical outcome. Moreover, in multivariate analysis,
DHRS9 still emerged as a significant independent predictor
of survival in addition to tumor stage. Thus, to our knowledge,
the current study is the first to report the prognostic value of
DHRS9 in CRC. Notably, our results revealed that TNM stage
also is a significant prognostic factor for CRC patients, which
is consistent with the well-recognized adverse prognostic ef-
fect of tumor stage [35] and confirms that our cohort was
representative and that the survival analyses were valid
(Table 3 and Fig. 3). More importantly, we demonstrated that
combination of DHRS9 protein expression with TNM stage
has a more powerful efficiency in prognosis prediction when
compared to each of the two parameters alone. Currently, the
underlying mechanism for the prognostic importance of
DHRS9 expression in CRC is not known and requires further
investigation; nevertheless, our data suggest that combination
of DHRS9 with TNM stage may have a better prognostic
value and could serve as a promising biomarker for classifi-
cation of CRC patients into distinct risk subgroups and guide
individualized therapy choices.
There were several limitations in the present study. Al-
though our results revealed the clinicopathologic correlation
and the prognostic value for DHRS9 expression in a cohort of
CRC patients, they did not elucidate the role of DHRS9 ex-
pression in the development of CRC. Besides, due to the lim-
itation of follow-up period, the median survival time of pa-
tients in the high DHRS9 expression group could not be ob-
tained; thus, our current results could not accurately reflect the
survival of patients in these subgroups. Additionally, the num-
ber of samples in the present study is still relatively small.
Therefore, futuremulti-center, prospective studies using larger
cohorts are necessary to verify the robustness of our findings
before clinical translation.
In conclusion, we here provided the first evidence that
DHRS9 protein expression was frequently downregulated in
CRC tissues and that decreased expression of DHRS9 was
significantly associated with disease progression and poor
outcome of CRC patients. Our data suggest that DHRS9 could
be used as a potential prognostic biomarker for CRC and that
combination of DHRS9 with TNM stage or other parameters
may enhance its performance in prognostic prediction. Apart
from its prognostic value, results from the present study en-
courage further investigation of its potential role in CRC
pathobiology.
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